Compare Abbott India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 47.1 36.9 127.6% View Chart
P/BV x 15.4 4.3 359.2% View Chart
Dividend Yield % 0.4 0.5 93.6%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
CIPLA
Mar-20
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs8,834586 1,508.8%   
Low Rs5,458357 1,529.6%   
Sales per share (Unadj.) Rs1,731.1207.0 836.1%  
Earnings per share (Unadj.) Rs211.918.6 1,139.6%  
Cash flow per share (Unadj.) Rs219.933.2 663.0%  
Dividends per share (Unadj.) Rs65.004.00 1,625.0%  
Dividend yield (eoy) %0.90.8 107.1%  
Book value per share (Unadj.) Rs945.2195.5 483.5%  
Shares outstanding (eoy) m21.25806.35 2.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.12.3 181.4%   
Avg P/E ratio x33.725.3 133.1%  
P/CF ratio (eoy) x32.514.2 228.8%  
Price / Book Value ratio x7.62.4 313.7%  
Dividend payout %30.721.5 142.6%   
Avg Mkt Cap Rs m151,848379,912 40.0%   
No. of employees `0003.525.8 13.5%   
Total wages/salary Rs m4,35630,270 14.4%   
Avg. sales/employee Rs Th10,555.56,459.6 163.4%   
Avg. wages/employee Rs Th1,249.91,171.2 106.7%   
Avg. net profit/employee Rs Th1,292.2580.2 222.7%   
INCOME DATA
Net Sales Rs m36,786166,949 22.0%  
Other income Rs m1,1333,442 32.9%   
Total revenues Rs m37,919170,391 22.3%   
Gross profit Rs m6,04732,060 18.9%  
Depreciation Rs m16911,747 1.4%   
Interest Rs m231,974 1.1%   
Profit before tax Rs m6,98921,782 32.1%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4856,312 39.4%   
Profit after tax Rs m4,50314,995 30.0%  
Gross profit margin %16.419.2 85.6%  
Effective tax rate %35.629.0 122.7%   
Net profit margin %12.29.0 136.3%  
BALANCE SHEET DATA
Current assets Rs m27,610117,038 23.6%   
Current liabilities Rs m8,56943,931 19.5%   
Net working cap to sales %51.843.8 118.2%  
Current ratio x3.22.7 120.9%  
Inventory Days Days6096 62.9%  
Debtors Days Days2785 32.2%  
Net fixed assets Rs m1,057107,424 1.0%   
Share capital Rs m2131,613 13.2%   
"Free" reserves Rs m19,873156,018 12.7%   
Net worth Rs m20,086157,630 12.7%   
Long term debt Rs m023,693 0.0%   
Total assets Rs m29,409236,626 12.4%  
Interest coverage x311.612.0 2,588.8%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.30.7 177.3%   
Return on assets %15.47.2 214.6%  
Return on equity %22.49.5 235.7%  
Return on capital %34.912.8 271.9%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36956,036 0.7%   
Fx outflow Rs m4,9186,764 72.7%   
Net fx Rs m-4,54949,272 -9.2%   
CASH FLOW
From Operations Rs m4,99130,685 16.3%  
From Investments Rs m-2,5701,040 -247.0%  
From Financial Activity Rs m-1,428-29,488 4.8%  
Net Cashflow Rs m9932,340 42.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 25, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PFIZER COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS